Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer
Our findings suggest that hemogram parameters and clinicopathological factors such as suboptimal surgery, lymphocyte count, SII, and bevacizumab therapy status are predictive markers for chemorefractory disease in advanced EOC. Elevated SII emerged as a predictor for poorer PFS and OS outcomes, particularly in the absence of bevacizumab therapy.
Authors
- Hung‐Chun Fu (ORCID: https://orcid.org/0000-0002-0660-9349)
- Yu‐Che Ou (ORCID: https://orcid.org/0000-0002-2849-5661)
- Hao Lin (ORCID: https://orcid.org/0000-0001-6265-2862)
- Yanping Fu
- Chen-Hsuan Wu
Institutions
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Chiayi Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1186/s12885-024-13087-8
- Citations
- 4
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.15
Funders
- Chang Gung Medical Foundation
- Kaohsiung Chang Gung Memorial Hospital